These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6522643)

  • 1. Plasma levels of neurotensin in gastroplasty for morbid obesity.
    Miskowiak J; Pedersen JH; Andersen B; Stadil F
    Regul Pept; 1984 Nov; 9(4):263-9. PubMed ID: 6522643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasting and meal-stimulated plasma levels of neurotensin in obese patients after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio.
    Pedersen JH; Sørensen TI; Andersen B; Stadil F
    Scand J Gastroenterol; 1987 Jan; 22(1):69-74. PubMed ID: 3563413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral fat on plasma levels of neurotensin and neurotensin fragments in humans. Characterization by high-pressure liquid chromatography.
    Draviam EJ; Upp JR; Greeley GH; Townsend CM; Thompson JC
    Dig Dis Sci; 1990 Feb; 35(2):200-4. PubMed ID: 2302977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meal stimulated neurotensin release following gastric partitioning for morbid obesity.
    Shulkes A; Allen RD; Hardy KJ
    Aust N Z J Surg; 1983 Apr; 53(2):149-52. PubMed ID: 6576763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma secretin before and after gastroplasty for morbid obesity.
    Miskowiak J; Andersen B; Stadil F; Schaffalitzky de Muckadell OB
    Scand J Clin Lab Invest; 1984 Jun; 44(4):363-5. PubMed ID: 6463566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meal stimulated levels of pancreatic polypeptide (PP) and vasoactive intestinal polypeptide (VIP) in gastroplasty for morbid obesity.
    Miskowiak J; Andersen B; Stadil F; Fahrenkrug J
    Regul Pept; 1985 Nov; 12(3):231-6. PubMed ID: 4081128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meal-stimulated neurotensin immunoreactivity in plasma following gastric surgery: characterisation with two region-specific antisera.
    Shaw C; Watt PC; Buchanan KD
    Digestion; 1986; 33(3):152-60. PubMed ID: 2419192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum gastrin and blood glucose levels in gastroplasty for morbid obesity.
    Miskowiak J; Andersen B; Stadil F; Holst Pedersen J
    Scand J Gastroenterol; 1984 Jul; 19(5):669-72. PubMed ID: 6474088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotensin-like immunoreactivities in human plasma: feeding responses and metabolism.
    Holst Pedersen J; Fahrenkrug J
    Peptides; 1986; 7(1):15-20. PubMed ID: 3714532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Behavior of plasma enteroglucagon and neurotensin in obese patients subjected to biliopancreatic bypass].
    Gianetta E; Bloom SR; Sarson DL; Civalleri D; Bonalumi U; Griffanti Bartoli F; Friedman D; Pitton L; Binda PL; Degrandi R; Scopinaro N
    Boll Soc Ital Biol Sper; 1980 Oct; 56(19):1915-21. PubMed ID: 7459102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitation and characterization of human plasma neurotensin-like immunoreactivity in response to a meal.
    Lee YC; Allen JM; Uttenthal LO; Roberts PM; Gill SS; Bloom SR
    Dig Dis Sci; 1985 Feb; 30(2):129-33. PubMed ID: 3838153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproduction of postprandial neurotensin plasma levels by intravenous neurotensin and the effect of neurotensin on exocrine pancreatic secretion in humans.
    Feurle GE; Hofmann G; Carraway R; Baća I
    Pancreas; 1986; 1(4):329-34. PubMed ID: 3562432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intact neurotensin (NT) in human plasma: response to oral feeding.
    Shaw C; Buchanan KD
    Regul Pept; 1983 Oct; 7(2):145-53. PubMed ID: 6197723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasting- and meal-stimulated peptide hormone concentrations before and after gastric surgery for morbid obesity.
    Meryn S; Stein D; Straus EW
    Metabolism; 1986 Sep; 35(9):798-802. PubMed ID: 3528741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of human plasma neurotensin-like immunoreactivity after fat ingestion.
    Theodorsson-Norheim E; Rosell S
    Regul Pept; 1983 Jul; 6(3):207-18. PubMed ID: 6622752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stability and metabolism of intravenously administered neurotensin in the rat.
    Aronin N; Carraway RE; Ferris CF; Hammer RA; Leeman SE
    Peptides; 1982; 3(4):637-42. PubMed ID: 7134032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotensin in diabetes and obesity.
    Service FJ; Jay JM; Rizza RA; O'Brien PC; Go VL
    Regul Pept; 1986 Mar; 14(1):85-92. PubMed ID: 3715064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of neurotensin and pancreatic polypeptide in man: role of the kidney and plasma factors.
    Shulkes A; Bijaphala S; Dawborn JK; Fletcher DR; Hardy KJ
    J Clin Endocrinol Metab; 1984 May; 58(5):873-9. PubMed ID: 6707191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial gut peptide plasma levels in women with idiopathic slow-transit constipation.
    Peracchi M; Basilisco G; Tagliabue R; Terrani C; Locati A; Bianchi PA; Velio P
    Scand J Gastroenterol; 1999 Jan; 34(1):25-8. PubMed ID: 10048728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radioimmunoassay for neurotensin in human plasma.
    Shulkes A; Chick P; Wong H; Walsh JH
    Clin Chim Acta; 1982 Oct; 125(1):49-58. PubMed ID: 7139948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.